Search

The article offers updates related to the development of drugs for the treatment of cancer patients in the U.S. The U.S. Food and Drug Administration (FDA) plans to review the Cell Therapeutics' new drug application (NDA) for pixantrone for the treatment of diffuse large B-cell lymphoma before the end of February 2010. EpiCept Corp. has entered into an exclusive commercialization with Sweden-based Meda Pharmaceuticals Inc. for ceplene as a treatment of patients with leukemia.

The article lists the latest reports related to pharmaceutical industries which include an in-depth review of the cardiovascular and metabolic markets, an overview of the current biologic molecular targeted therapies pipeline in oncology, and a report that explores key issues in Hepatitis B and C in Asian markets.

The article lists the latest reports related to pharmaceutical research in the U.S. including the "Pipeline Insight: Biologic Targeted Cancer Therapies Next Generation Jostles for Market Position," "Pipeline Insight: Multiple Sclerosis - Risk-Benefit Ratio Under the Spotlight for Potent Pipeline Drugs," and "Stakeholder Opinions: Therapeutics Vaccines - A far-off promise of Greatness."

The article presents the Strength Weakness Opportunities and Threat (SWOT) analysis of biotechnology company Genmab Inc. Its strengths include several late stage development programs and weaknesses include lack of partners for the development of Zalutumumab. Its opportunities and threats include biologics license application for Arzerra in the treatment of chronic lymphocytic leukaemia and Healthcare reforms and cost containment measures respectively.

The article offers news briefs related to pharmaceutical industry in the U.S. A new drug application has been submitted by Allos Therapeutics Inc. to the Food and Drug Administration (FDA) for the use of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Meanwhile, an agreement has been signed by Takeda Pharmaceutical Co. Ltd. with Wyeth for the product license for Prostap. Firmagon has been launched by Ferring Pharmaceuticals Inc.

The article reports that Bayer Schering made a positive performance during the first half of the year and a second quarter sale due to product lines like Yasmin and Betaferon. However, the pharmaceutical company's focus is on the new oncology treatment Nexavar. The company is engaged in developing, manufacturing and selling pharmaceutical products for gynecology, andrology and oncology markets. Bayer Schering's also offers products for multiple sclerosis.

The article offers global news briefs related to pharmaceutical industry. A clinical trial conducted by researchers at the Washington School of Medicine has assessed the capability of the micro-array riboleukogram, based on gene chip technology, in detecting early indicators of immune responses to infection before clinical signs of disease occur. Celgene Corp. has closed its acquisition of Pharmion Corp. for $2.9 billion. PDL BioPharma Inc. plans to renew its focus on research and development.

The article offers news briefs related to cancer therapy. Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. have cut their Phase III trial of Nevaxar for non-small cell lung cancer. The Horizon III Phase II/III study of Recentin in patients with first line metastatic colorectal cancer by AstraZeneca PLC will progress into Phase III. Next generation anticancer compounds of PhytoMedical Technologies Inc. were found to kill difficult-to-treat human cancer cells.

The article offers news briefs related to cancer treatment. Study shows that the combination therapy of Cell Therapeutics is effective in treating non-follicular indolent non-Hodgkin's lymphoma (NHL). The ICA-1 compound of Inhibition Therapeutics is found effective in laboratory in-vitro testing in various cancer cell lines. Genzyme has signed a licence agreement with Moffitt Cancer Canter (MCC) for lung cancer diagnostic.